← Evidence map

ArticlePloS one2026

Assessing the real-world safety of vutrisiran for transthyretin-mediated amyloidosis with polyneuropathy: Based on WHO-VigiAccess and FAERS databases.

Weiwei Tong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Assessing the real-world safety of vutrisiran for transthyretin-mediated amyloidosis with polyneuropathy: Based on WHO-VigiAccess and FAERS databases. | OpenQuestion